Evidence map›Paper›PMID 33062421›Full record

ArticlePeerJ2020

Differential effects of cisplatin on cybrid cells with varying mitochondrial DNA haplogroups.

Sina Abedi, Gregory Yung, Shari R Atilano, Kunal Thaker, Steven Chang, Marilyn Chwa, Kevin Schneider, Nitin Udar, Daniela Bota, M Cristina Kenney

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PeerJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Insights into the Role of Oxidative Stress in Ovarian Cancer.Oxidative medicine and cellular longevity · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Sina AbediGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Gregory YungGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Shari R AtilanoGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Kunal ThakerGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Steven ChangGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Marilyn ChwaGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Kevin SchneiderGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Nitin UdarGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
Daniela BotaDepartment of Neurology, Neuro-Oncology Division, University of California, Irvine CA, United States of America.
M Cristina KenneyGavin Herbert Eye Institute, University of California, Irvine, Irvine, CA, United States of America.
University of California, Irvine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDrug therapy yields different results depending on its recipient population. Cisplatin, a commonly used chemotherapeutic agent, causes different levels of resistance and side effects for different patients, but the mechanism(s) are presently unknown. It has been assumed that this variation is a consequence of differences in nuclear (n) DNA, epigenetics, or some external factor(s). There is accumulating evidence that an individual's mitochondrial (mt) DNA may play a role in their response to medications. Variations within mtDNA can be observed, and an individual's mtDNA can be categorized into haplogroups that are defined by accumulations of single nucleotide polymorphisms (SNPs) representing different ethnic populations.

methodsThe present study was conducted on transmitochondrial cytoplasmic hybrids (cybrids) that possess different maternal-origin haplogroup mtDNA from African (L), Hispanic [A+B], or Asian (D) backgrounds. Cybrids were created by fusing Rho0 ARPE-19 cells (lacking mtDNA) with platelets, which contain numerous mitochondria but no nuclei. These cybrid cells were cultured to passage five, treated with cisplatin, incubated for 48 h, then analyzed for cell metabolic activity (tetrazolium dye (MTT) assay), mitochondrial membrane potential (JC-1 assay), cytotoxicity (lactate dehydrogenase (LDH) assay), and gene expression levels for

resultsResults indicated that untreated cybrids with varying mtDNA haplogroups had similar relative metabolic activity before cisplatin treatment. When treated with cisplatin, (1) the decline in metabolic activity was greatest in L (27.4%,

conclusionOur findings suggest that an individual's mtDNA background may be associated with variations in their response to cisplatin treatment, thereby affecting the efficiency and the severity of side effects from the treatment.

Indexed as

AnticancerARPE-19CisplatinCybridsDrug resistanceMitochondriamtDNA haplogroupsPharmacogenomics

Identifiers

PMID33062421
PMCPMC7533064
OpenAlexW3091488432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.